Details for New Drug Application (NDA): 209511
✉ Email this page to a colleague
NDA 209511 describes XARACOLL, which is a drug marketed by Innocoll Pharms and is included in one NDA. There are two patents protecting this drug. Additional details are available on the XARACOLL profile page.
The generic ingredient in XARACOLL is bupivacaine hydrochloride. There are twelve drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the bupivacaine hydrochloride profile page.
The generic ingredient in XARACOLL is bupivacaine hydrochloride. There are twelve drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the bupivacaine hydrochloride profile page.
Summary for 209511
| Tradename: | XARACOLL |
| Applicant: | Innocoll Pharms |
| Ingredient: | bupivacaine hydrochloride |
| Patents: | 2 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | IMPLANT;IMPLANTATION | Strength | 100MG | ||||
| Approval Date: | Aug 28, 2020 | TE: | RLD: | Yes | |||||
| Patent: | ⤷ Subscribe | Patent Expiration: | Jan 9, 2033 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patent: | ⤷ Subscribe | Patent Expiration: | May 20, 2029 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | A METHOD FOR INDUCING A POST-SURGICAL ANALGESIA SPARING EFFECT BY IMPLANTING AT THE SURGICAL SITE A COLLAGEN SPONGE CONTAINING BUPIVACAINE HCL WHICH PROVIDES LOCAL ANESTHESIA FOR UP TO 24 HOURS FOLLOWING IMPLANTATION | ||||||||
Complete Access Available with Subscription
